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Both oral anticoagulant (AC) and antiplatelet (AP) therapy are effective in reducing mortality In patients (pis) with cardiovascular disease. The outcome of the trials of combined AC/AP compared to AC alone, AP alone or placebo is promising, but its safety is a matter of concern.
In the 6 published trials of combined AC/AP directly comparing reference therapy (AC, AP or placebo) 4,874 pts were randomized. High intensity AC (AC) INR > 2.5 was combined with high (> 500 mg aspirin qd) dose AP (AF) in 3 trials, and with low (< 100 mg aspirin qd) dose AP (ap) in 2 trials. Low intensity AC (ac) INR Thoracic inferior vena cava constriction (TIVCC) is an experimental model of heart failure characterized by a decrease in cardiac output and an increase in plasma endothelin (ET) concentrations. ET, a coronary vasoconstrictor, mediates its activity through two specific receptors (ET-A and ET-B), which demonstrate different activity levels in pathophysiological conditions. The current study was designed to test the hypothesis that experimental heart failure is characterized by an enhanced coronary vasoconstriction to the ET-B receptors activation. Sarafotoxin (an ET-B receptor agonist) at 2 ng/kg/min was infused into the left circumflex coronary artery in normal (n = 5) and TIVCC (n = 5) anesthetized dogs. Plasma ET was elevated in the TIVCC dogs as compared to the Normal group (37 ± 5 vs. 17 ± 3, p < 0.05)
Normal TIVCC % A CBF -7 ± 8 -31 ± 4* % A CVR 12±8 53 dr 12* % A CAD 1.9 ±0,7 2.1 ±1.9
%A from baseline, CBF = coronary blood flow, CVR = coronary vascular resistance, CAD = coronary artery diameter; *p < 0.05 between normal vs. TIVCC.
These studies demonstrate an enhanced coronary vasoconstrictor re sponse to sarafotoxin in experimental heart failure which is chiefly localized to the microcirculation. This study suggests an alteration in coronary ET-B receptor activity in heart failure and underscores the importance of the ET-B receptors in the control of coronary vascular tone this condition.
Indications for Lipid Management
Monday, March 25, 1996 NCEP guidelines stipulate that LDL-cholesterol (LDL-C) should be reduced to the same level in all coronary patients, to < 100 mg/dl. But a recent secondary analysis of the 4S data showed that the decrease in LDL-C with simvastatin (32-37%) and the decrease in relative risk (32-36% ) were comparable across atl quartiles of baseline LDL-C, despite differences in on-trial LDL-C (Lancet 1995; 345:1274) . To test the hypothesis that the reduction in LDL-C correlates better with outcome than the on-treatment level of LDL-C, we ex amined the 24 control and treatment groups from the 11 cholesterol-lowering coronary angiographic trials (FATS, SCOR, STARS, Lifestyle, MARS, CCAIT, HARP, SCRIP, MAAS, FHRS and PLAC-1) with quantitative measurements of lesion percent diameter stenosis change (A%DS). Mean A%DS ranged from +5.8 (progression) to -2 .5 (regression), mean on-trial LDL-C varied from 86 to 242 mg/dl and change in LDL-C ranged from +3% to -53% . Lin ear regression analysis was performed with the groups weighted according to their size.
Results:
The relationship between on-trial LDL-C levels and A%DS was weak: r = 0.36, p = 0.086. However, a strong relationship was seen between % change in LDL-C and A%DS (A%DS = 3.18 + 0.071 x %ALDL-C; r = 0.74, p < 0.0005). According to the equation, a 44% reduction of LDL-C is needed to arrest coronary progression. Lowering elevated LDL-Cholesterol (LDL-C) in patients with documented CAD reduces morbidity and mortality. NCEP guidelines in this population are based on LDL-C levels, with a target level of < 100 mg/dl. In order to assess physician compliance with NCEP guidelines, we reviewed the care of all patients under 75 years of age discharged with the diagnosis of acute Ml in 1994 in our institution. Mean follow-up was 9.6 db 0.8 months (range 4-15) .
Of 114 patients with the diagnosis of acute Ml, 30 (26%) had known hyper LDL-C prior to their Ml. Of these only 6/30 (20%) had documented LDL-C in the target range on follow-up. In 7/30 (23%) no therapy was instituted, while in 17/30 (57%) target LDL-C level was either not achieved or not documented.
Of the 84 patients (74%) without known hyperlipidemia, six had evaluation and therapy per NCEP guidelines. An incomplete evaluation (only total-C or profile obtained during acute illness) was performed in 44/84 (52%) while 16/84 (19%) had no iipid evaluation at all. No therapy was instituted in 18/84 (21%) who met NCEP criteria for therapy.
Overall, only 12/114 (11%) patients were evaluated according to NCEP guidelines and had documentation of achieving treatment goals. In contrast, 100% of patients were prescribed ASA (p < 0.001), another recommended therapy in patients with CAD.
Thus physician compliance with NCEP guidelines in this study was low, with most patients not having LDL-C based evaluation and therapy. Greater effort has to be made in educating physicians in lipid management post Ml. 
